Home - Sana Biotechnology
Sana is creating engineered cells to repair and control genes in cells or replace missing or damaged cells to solve the underlying causes of disease.
Sana Biotechnology, Inc. (SANA) Stock Price, News, Quote
Find the latest Sana Biotechnology, Inc. (SANA) stock quote, history, news and other vital information to help you with your stock trading and investing.
Join Us - Sana Biotechnology
At Sana, we believe that a diverse workforce strengthens us as a company and a community, which is essential for us to meaningfully change outcomes for patients across a wide range of …
Sana Biotechnology Announces Positive Clinical Results from …
Jan 7, 2025 · First-in-Human Study Provides Evidence that Sana’s Hypoimmune (HIP) Technology Enables Transplanted Islet Cells to Avoid Immune Rejection and Produce Insulin …
Our Team - Sana Biotechnology
Sana's team includes executives, board members, investors, and scientists with deep experience in cell and gene therapy.
Sana Biotechnology Announces Positive Clinical Results from …
Jan 7, 2025 · Results Demonstrate HIP-Engineered Primary Pancreatic Islet Cells Avoid Immune Detection, Function, and Persist after Intramuscular Transplantation in First Treated Patient with Type 1 Diabetes.
Investor Relations | Sana Biotechnology, Inc
Dec 2, 2024 · Sana Biotechnology, Inc. is focused on creating and delivering engineered cells as medicines for patients. We share a vision of repairing and controlling genes, replacing missing or damaged cells, and making our therapies broadly available to patients.
Is Sana Biotechnology, Inc. (SANA) the Hottest Smid-Cap Stock …
6 days ago · We recently compiled a list of the 10 Hottest Smid-Cap Stocks So Far In 2025. In this article, we are going to take a look at where Sana Biotechnology, Inc. (NASDAQ:SANA) stands against the other ...
Sana strips back cancer, CNS programs while warning of layoffs
Nov 5, 2024 · Sana Biotechnology has become the latest cell therapy biotech to shift resources from cancer to autoimmune diseases as part of a strategic refocus that sounds likely to include a side order...
Sana stock price triples after allogeneic cell therapy data drop
Jan 8, 2025 · Sana Biotechnology has shared early data for its investigational allogeneic cell therapy being studied in one patient with type 1 diabetes, sending the company’s share price up by about 200%.
- Some results have been removed